FDA

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.

Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

Officials say the recall was prompted after a random sample tested positive for the organism listeria monocytogenes. No illnesses have been reported, the FDA says.

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.

The FDA has issued new targets to reduce the amount of salt that manufacturers put in their foods. It could prevent thousands of cases of cardiovascular disease.

Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.